Eli Lilly Strikes $1.3 Billion Deal With Superluminal To Develop AI-Driven Obesity Drugs BY Namrata Sen • August 15, 2025August 15, 2025 Eli Lilly and Co (NYSE:LLY) has entered into a $1.3 billion deal with Superluminal Medicines to develop small-molecule drugs through artificial intelligence (AI) to treat obesity and other cardiometab[...] Read more
